Tag

Glp 1gipglucagon

All articles tagged with #glp 1gipglucagon

business1 month ago•3 min saved

Lilly targets 2027 filing for next-gen obesity drug retatrutide after strong Phase 3 results

Eli Lilly said it will file for retatrutide's approval in Q1 2027 after two positive Phase 3 trials showing substantial weight loss and improved glycemic control in adults with obesity and either Type 2 diabetes or cardiovascular disease; the company needs more time to finalize manufacturing data, and retatrutide—a triple-hormone GLP-1/GIP/glucagon drug—could become a key obesity treatment alongside Zepbound and Foundayo.

via CNBC|

#business #eli-lilly #glp-1gipglucagon

business3 months ago•5 min saved

Lilly’s triple-hormone retatrutide shows leading obesity trial results

Phase 3 data show Lilly’s investigational triple-hormone drug retatrutide delivering up to 28.3% average weight loss over 80 weeks at the highest dose (vs. 2.2% placebo), with about 45% of patients achieving 30%+ loss and even greater reductions in those with BMI ≥35. A lower 4 mg dose yielded 19% weight loss with better tolerability. Common side effects were GI (nausea, diarrhea, constipation); no major cardiac or liver issues were observed. If results hold, Lilly could file for approval, potentially solidifying retatrutide as a top player in a booming obesity market, ahead of Novo Nordisk’s competing therapies.

via CNBC|

#business #eli-lilly #glp-1gipglucagon